U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Obesity and Metabolism Research: Davis, CA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Laboratories
                        Bennett Group
                                    Huang Group
                                    Keim Group
                                    Laugero Group
                                    Newman GroupSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Pacific West Area Davis, California Western Human Nutrition Research Center Obesity and Metabolism Research Research Publications at this Location





- ARS National Programs
- Search for a scientific manuscript
- Search for a research project
- ARS Software
- Programs and Projects
- Collaborations
- Subjects of Investigation
- Publications

Title:   Author  item
                                            MACK, CHRISTINE - Amylin Pharmaceuticals, Incitem
                                            SOARES, CHRISTOPHER - Amylin Pharmaceuticals, Incitem
                                            WILSON, JULIE - Amylin Pharmaceuticals, Incitem
                                            ATHANACIO, B - Amylin Pharmaceuticals, Incitem
                                            TUREK, VICTORIA - Amylin Pharmaceuticals, Incitem
                                            TREVASKIS, JAMES - Amylin Pharmaceuticals, Incitem
                                            ROTH, JONATHAN - Amylin Pharmaceuticals, Incitem
                                            SMITH, PAMELA - Amylin Pharmaceuticals, Incitem
                                            GEDULIN, BRONISLAVA - Amylin Pharmaceuticals, Incitem
                                            JODKA, CAROLYN - Amylin Pharmaceuticals, Incitem
                                            ROLAND, BARBARA - Amylin Pharmaceuticals, Incitem
                                            Adams, Seanitem
                                            LWIN, AUNG - Amylin Pharmaceuticals, Incitem
                                            HERICH, JOHN - Amylin Pharmaceuticals, Incitem
                                            Laugero, Kevinitem
                                            VU, CALVIN - Amylin Pharmaceuticals, Incitem
                                            PITTNER, RICHARD - Amylin Pharmaceuticals, Incitem
                                            PATERNITI, JAMES - Amylin Pharmaceuticals, Incitem
                                            HANLEY, MICHAEL - Amylin Pharmaceuticals, Incitem
                                            GHOSH, SOUMITRA - Amylin Pharmaceuticals, Incitem
                                            PARKES, DAVID - Amylin Pharmaceuticals, Inc
  Submitted to: International Journal of Obesity
                                    Publication Type: Peer Reviewed Journal
                                    Publication Acceptance Date: 9/6/2009
                                    Publication  Date: 11/24/2009
                                    Citation: Mack, C.M., Soares, C.J., Wilson, J.K., Athanacio, B.A., Turek, V., Trevaskis, J., Roth, J., Smith, P.A., Gedulin, B., Jodka, C.M., Roland, B.L., Adams, S.H., Lwin, A., Herich, J., Laugero, K.D., Vu, C., Pittner, R., Paterniti, J.R., Hanley, M., Ghosh, S., Parkes, D.G. 2009. Davalintide (AC2307), a Novel Amylin Mimetic Peptide: Enhanced Pharmacological Properties over Native Amylin to Reduce Food Intake and Body Weight. International Journal of Obesity. 34, 385-395, 2010.Interpretive Summary: This paper describes studies that examined the actions of a new amylin hormone mimetic peptide davalintide (AC2307) in rodents, and compared the effects of davalintide to those of the native peptide hormone, amylin. Davalintide reduced energy intake and body weight and fat composition to a greater degree than did amylin, but this new peptide retained the beneficial properties (e.g., fat specific weight loss; maintenance of energy expenditure in light of body weight loss; reduced preference for highly palatable food). Findings also suggest that davalintide and amylin act through a similar mechanism in the brain to impart its effects on food intake and body weight. Together, this work suggests that davalintide may have therapeutic potential as an antiobesity agent.
                                Technical Abstract: Objective: These studies describe the in vivo metabolic actions of the novel amylin mimetic peptide davalintide (AC2307) in rodents, and compare these effects to those of the native peptide.
Research Design and Methods: The anti-obesity effects of davalintide were examined following intraperitoneal injection or sustained peripheral infusion via subcutaneously implanted osmotic pumps. The effect of davalintide on food intake following lesion of the area postrema (AP), and neuronal activation as measured by c-Fos, were also investigated. 
Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin, and calcitonin gene-related peptide receptors. Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared to amylin (23 versus 6 h). Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. Davalintide-induced weight loss via infusion was dose-dependent, durable up to 8 weeks, fat-specific and lean-sparing, and associated with a shift in food preference away from high-fat (palatable) chow. Metabolic rate was maintained during active weight loss. Both davalintide and amylin failed to suppress food intake following lesion of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared to amylin (8 versus 2 h). 
Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native molecule. In vitro receptor binding, c-Fos expression, and AP lesion studies suggest the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov